Self-reported health-related quality of life in persons with HIV infection: results from a multi-site interview project

Michael L Campsmith*1, Allyn K Nakashima1 and Arthur J Davidson2

Address: 1Division of HIV/AIDS Prevention, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA and 2Denver Department of Public Health, Denver, Colorado, USA

Email: Michael L Campsmith* - mcampsmith@cdc.gov; Allyn K Nakashima - anakashima@cdc.gov; Arthur J Davidson - art.davidson@dhha.org

* Corresponding author

Abstract

Background: To examine demographic and behavioral associations with self-reported health-related quality of life (HRQOL) among persons with HIV infection or AIDS.

Methods: Analysis of interviews with persons ≥ 18 years of age reported through routine disease surveillance with HIV infection or AIDS to nine state and local health departments from January 1995 through December 1996. Scales were constructed from validated measures of HRQOL, and mean scores were calculated (lower scores signified poorer HRQOL). Measures of HRQOL included Overall Health, Pain, Physical Functioning, Role Functioning, Social Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning. Differences in HRQOL were examined by various demographic and behavioral factors, including taking antiretroviral medication.

Results: HRQOL data were available for 3778 persons. Factors associated with lower HRQOL scores included older age, female sex, black or Hispanic race/ethnicity, injection drug use, lower education and income, no private health insurance, and lower CD4 count. In multivariate analysis, lower CD4 count was the factor most consistently associated with lower HRQOL. Taking antiretroviral medication was not associated with differences in HRQOL regardless of CD4 count.

Conclusions: Perception of HRQOL varied in a population with HIV infection or AIDS. On most HRQOL measures, lower CD4 count was associated with lower HRQOL. Measurement of HRQOL can assist in understanding the long-term effects of disease and treatment on persons with HIV.

Background

New antiretroviral therapies introduced in the mid 1990s have allowed many persons with HIV infection to live longer before progressing to AIDS, and to have longer survival following an AIDS diagnosis [1–3]. The annual number of deaths due to AIDS in the United States peaked in 1995 and has since declined [4], resulting in an increase in the number of prevalent AIDS cases. Current clinical guidelines [5] call for persons infected with HIV to take a combination of antiretroviral medications to decrease viral load, maintain immune cell function, and prevent the development of resistant viral strains. Thus, for many pa-
tients the treatment of HIV has evolved more toward a model of chronic disease management, with patients taking a variety of potent medications for extended periods of time.

Besides clinical outcomes, health-related quality of life (HRQOL) and disability are important issues for persons treated for chronic diseases [6–11], including HIV infection [12–14]. Populations with HIV infection or AIDS have reported different levels of HRQOL, both in clinical trials [15–18] and population-based research [19–21]. We present summary information from a multi-site supplemental surveillance project that describes the levels of HRQOL reported by HIV-infected persons in different demographic and behavioral risk factor groups, stressing the relationship between disease progression and HRQOL.

**Methods**

Since 1990, the Centers for Disease Control and Prevention (CDC) has conducted the Supplement to HIV/AIDS Surveillance (SHAS) Project, an ongoing cross-sectional interview study designed to collect supplemental behavioral surveillance data from persons with HIV infection [22]. Persons 18 years of age or older reported with HIV or AIDS through routine case surveillance were eligible for participation. Participants were enrolled using one of three methods: (1) facility-based recruitment of all eligible persons seeking treatment at selected health care facilities in Atlanta, Connecticut, Denver, Detroit, Florida, and New Jersey; (2) population-based recruitment of all eligible persons in Arizona, Delaware, New Mexico and South Carolina; and (3) population-based recruitment of a 30% sample of men who have sex with men (MSM) and 100% of all other eligible persons in Washington State and Los Angeles County, California. During the period examined for this analysis, Arizona, Denver, Detroit, New Jersey, and South Carolina interviewed persons with HIV infection in addition to those with AIDS. (Three sites-Detroit, South Carolina, and Washington-opted not to collect data using the HRQOL module and were excluded from all analyses.) Informed consent was obtained from all participants prior to the interview, and the study has received institutional review board approval at both the CDC and local levels. Trained interviewers conducted a standardized interview in either English or Spanish that includes questions on demographic characteristics, drug and alcohol use, sexual behaviors, and medical and social service information. Data are self-reported and are not verified through medical record review or clinical tests. On average, interviews take approximately 45 minutes to complete. Data were sent to CDC without any personal identifying information.

The format of the SHAS Project allows the questionnaire to be modified to collect data on additional topics of interest. From January 1995 through December 1996, a module of questions adapted from research conducted by Albert Wu and colleagues [23] was added to study the levels of self-reported HRQOL. Wu et al compiled questions from the RAND Medical Outcomes Study (MOS) [24] as well as additional items to measure other dimensions of health (energy, distress, and cognitive function) potentially relevant to HIV disease. Wu et al found that their modified health status questionnaire reliably and distinctly measured aspects of health among HIV-positive persons recruited for two clinical trials of zidovudine. HIV-infected persons who were asymptomatic had higher scores on most HRQOL dimensions-indicating relatively less disability and a better quality of life-than persons who were diagnosed with early AIDS related complex.

Analysis of variance tests were used to compare crude mean HRQOL scores across demographic and behavioral categories; because the sample was large the significance level for univariate analysis was set at P < 0.01. Multivariate linear regression (least-squares means) was used to identify independent factors associated with HRQOL in the statistical models; analyses included variables noted from the literature as potentially associated with quality of life (e.g., age, sex, education, and income). Linear regression models were then constructed using the separate HRQOL dimension scores as the outcomes; here, the significance level was set at P < 0.05. Tukey-Kramer adjustments for multiple comparisons were used where appropriate. Age and education were included in the models as continuous predictor variables; CD4 count, gender, income, race/ethnicity, mode of exposure, time known to be HIV+, currently taking antiretroviral therapy (yes versus no), and type of SHAS recruitment (population-based versus facility-based) were included as categorical predictor variables. To simplify comparisons across HRQOL dimensions, we report results for models including all predictor variables, regardless of whether any indi-
individual variable was predictive of the outcome. All analyses were conducted using SAS Version 6.12 (SAS Institute, Inc., Cary, NC, USA).

Results
From January 1995 through December 1996, 6128 persons were identified for interview at the nine sites that administered the HRQOL module. Of these, 614 were found to have died before they could be contacted. Of the remaining 5514, 4246 (77.0%) completed SHAS interviews, 463 (8.4%) refused to participate, 394 (7.1%) could not be located, and 353 (6.4%) were located but were too ill (either physically or mentally) to participate. Sites phased out the HRQOL module at various times during the two-year period; HRQOL data were available from 3778 interviews. Persons administered the HRQOL module were demographically similar to persons who did not participate in SHAS (refused, could not be located, or too ill), except that a slightly higher percentage of those who did not participate were male (76.0% vs. 73.5%) and white (40.5% vs. 34.0%; chi-square test of proportions, P < 0.001).

The multi-item HRQOL dimensions of Physical Functioning, Role Functioning, Mental Health, Energy/Fatigue, and Cognitive Functioning were internally consistent in our sample (Table 1; all Cronbach’s alpha ≥ 0.84).

| Measures                 | Definition                                      | Number of Items | Cronbach’s Alpha |
|--------------------------|-------------------------------------------------|-----------------|------------------|
| Overall Health           | Perception of current health                    | 1               | –                |
| Pain                     | Perception of overall pain                      | 1               | –                |
| Physical Functioning     | Extent to which health interferes with a variety of activities | 6               | 0.84             |
| Role Functioning         | Extent to which health interferes with usual daily activities | 2               | 0.89             |
| Social Functioning       | Extent to which health interferes with normal social activities | 1               | –                |
| Mental Health            | General mood or affect, including depression, anxiety, well-being | 5               | 0.85             |
| Energy/Fatigue           | Extent to which patient felt fatigued            | 4               | 0.87             |
| Cognitive Functioning    | Extent to which reasoning or concentration was impaired | 4               | 0.88             |

* a measure of internal consistency reliability for multi-item scales

Mean HRQOL scores were stratified across demographic and behavioral categories and compared by using the analysis of variance. As seen in Table 2, lower Overall Health scores were associated with older age, female sex, black or Hispanic race/ethnicity, HIV exposure through injection drug use, lower CD4 count, less than 12 years of education, no private health insurance, and lower income. Mean scores for each of the remaining HRQOL dimensions were also computed and similarly compared by demographic characteristics. In most instances in which significant differences were found, lower HRQOL was associated with the factors already listed (data not displayed).

In linear regression analyses, lower CD4 count, less education, lower income, and older age were consistently associated with lower HRQOL scores. Table 3 shows the HRQOL scores stratified by CD4 count adjusted for the other predictor variables, using the Least Squares Means technique (the group labeled "CD4 Unknown" includes those who never had a CD4 test as well as those who had a CD4 test but could not recall the result). On all but two of the HRQOL measures, self-reported HRQOL decreased as CD4 count decreased. CD4 count was not associated with the measures of Mental Health and Cognitive Function.

We were also interested in the relationship between antiretroviral therapy and HRQOL. Most of the study population (65.0%) was currently taking antiretroviral medication. Taking antiretroviral medication differed significantly by CD4 count: 75.1% of those with a CD4 count of <200 were currently taking antiretroviral medication, compared to 68.5% with a CD4 count of 200–499, and 27.3% with a CD4 count of ≥ 500 (P < 0.001, Mantel Hantzel chi-square test for trend). In univariate analysis, current antiretroviral therapy was associated with only two HRQOL dimensions: therapy was negatively associated with Role Function and positively associated with Mental Health. For the dimension of Role Function,
currently taking antiretroviral medication was associated with a lower HRQOL score (44.3) than that of persons not currently taking medication (49.8; $P < 0.001$). However, in the multivariate models examining HRQOL scores stratified by CD4 count, currently taking antiretroviral medication was not associated with differences in HRQOL.

Table 2: Overall Health score by demographic variables (N = 3778)

| Variable                      | Number (%) | HRQOL Measure – Overall Health score<sup>a</sup> | Change from reference |
|-------------------------------|------------|-----------------------------------------------|-----------------------|
| Age, years                    |            |                                               |                       |
| 18–29                         | 605 (16.0) | 55.7 (ref.)                                   |                       |
| 30–39                         | 1783 (47.2)| 51.4<sup>b</sup>                              | -4.3                  |
| 40–49                         | 1055 (27.9)| 47.2<sup>c</sup>                              | -8.5                  |
| ≥50                           | 335 (8.9)  | 45.4<sup>c</sup>                              | -10.3                 |
| Gender                        |            |                                               |                       |
| Male                          | 2778 (73.5)| 51.3 (ref.)                                   |                       |
| Female                        | 1000 (26.5)| 47.7<sup>c</sup>                              | -3.6                  |
| Race/ethnicity                |            |                                               |                       |
| White                         | 1286 (34.0)| 54.4 (ref.)                                   |                       |
| Black                         | 1547 (41.0)| 48.5<sup>c</sup>                              | -5.9                  |
| Hispanic                      | 901 (23.8) | 47.8<sup>c</sup>                              | -6.6                  |
| Other                         | 44 (1.2)   | 50.5                                          | -3.9                  |
| Mode of exposure              |            |                                               |                       |
| MSM                           | 1481 (39.2)| 56.3 (ref.)                                   |                       |
| IDU                           | 982 (26.0) | 42.1<sup>c</sup>                              | -14.2                 |
| MSM/IDU                       | 310 (8.2)  | 51.1                                          | -5.2                  |
| Heterosexual contact          | 691 (18.3) | 49.7<sup>c</sup>                              | -6.6                  |
| Other (includes NIR)          | 314 (8.3)  | 49.0<sup>c</sup>                              | -7.3                  |
| Most recent CD4 count         |            |                                               |                       |
| <200                          | 1950 (56.4)| 46.7 (ref.)                                   |                       |
| 200–499                       | 812 (23.5) | 58.0<sup>c</sup>                              | +11.3                 |
| ≥500                          | 259 (7.5)  | 64.9<sup>c</sup>                              | +18.2                 |
| Unknown                       | 433 (12.5) | 48.7                                          | +2.0                  |
| Education                     |            |                                               |                       |
| <12 years                     | 1329 (35.2)| 44.7 (ref.)                                   |                       |
| ≥12 years                     | 2449 (64.8)| 53.4<sup>c</sup>                              | +8.7                  |
| Health insurance status       |            |                                               |                       |
| Private insurance             | 443 (12.7) | 60.3 (ref.)                                   |                       |
| Public insurance              | 1889 (54.0)| 47.2<sup>c</sup>                              | -13.1                 |
| None                          | 1167 (33.3)| 52.3<sup>c</sup>                              | -8.0                  |
| Income                        |            |                                               |                       |
| <$10,000/year                 | 2135 (61.1)| 47.1 (ref.)                                   |                       |
| ≥$10,000/year                 | 1357 (38.9)| 57.2<sup>c</sup>                              | +10.1                 |
| Time HIV+ status known        |            |                                               |                       |
| <12 month                     | 1091 (29.1)| 52.1 (ref.)                                   |                       |
| ≥12 months                    | 2662 (70.9)| 49.7                                          | -2.4                  |
| Current antiretroviral therapy|            |                                               |                       |
| Yes                           | 2380 (65.0)| 50.8 (ref.)                                   |                       |
| No                            | 1279 (35.0)| 50.1                                          | -0.7                  |
| Type of recruitment           |            |                                               |                       |
| Facility-based                | 2386 (63.2)| 49.5 (ref.)                                   |                       |
| Population-based              | 1392 (38.4)| 51.8                                          | +2.3                  |

<sup>a</sup> analysis of variance; Tukey-Kramer adjustment for multiple comparisons;  
<sup>b</sup> = $P < 0.01$;  
<sup>c</sup> = $P < 0.001$;  
ref. = reference group; MSM = men who have sex with men; IDU = injection drug use; MSM/IDU = men who have sex with men and injection drug use; NIR = no identified risk.
Discussion

Disability and health-related quality of life are becoming increasingly important issues associated with HIV disease. New developments in the treatment of HIV have produced dramatic improvements in the clinical and immunologic health for many patients, with a resulting reduction in deaths due to AIDS in the United States. Along with clinical indicators of morbidity and mortality, measures of HRQOL (such as physical functioning, mental health, pain, and energy) can help guide treatment decisions for both patients and providers.

Like other researchers, we found that lower HRQOL scores and poorer perception of health were associated with more advanced disease. A majority of the SHAS participants had an AIDS diagnosis at the time of their interview. However, a broad range of CD4 levels is represented in the study population. Along with clinical indicators of morbidity and mortality, measures of HRQOL (such as physical functioning, mental health, pain, and energy) can help guide treatment decisions for both patients and providers.

Several limitations should be considered in the interpretation of our findings. SHAS is a cross-sectional interview study with data self-reported by the participant. Critical indicators of disease progression, such as CD4 count, were not confirmed through clinical testing or review of medical records. Among those who reported having ever had a CD4 count, 12.5% could not recall the most recent CD4 count; on most HRQOL dimensions their scores lay between the scores for the lowest and middle CD4 groups. This finding suggests they were more advanced in their HIV disease; indeed, 83.6% were reported to the national surveillance system as having AIDS. The SHAS questionnaire also did not adequately capture the composition of a person's past and current antiretroviral therapies, or the duration of, and adherence to, those therapies. Specifically, this questionnaire does not assess the effects of protease inhibitor therapy on HRQOL, as those medications were introduced during the period the HRQOL module was used. Of the 2380 persons taking antiretroviral medications at the time of interview, only 39 (1.6%) reported taking protease inhibitors. Although other studies have also reported that questions adapted from the MOS discriminated differences in HRQOL among populations with HIV [15–19], the SHAS questionnaire's shorter 24-item subset of the MOS questions may limit direct comparison of our results with those of other studies. Still, our findings from the HRQOL analysis in SHAS generally agree with those in other published research.

Quality of life issues are also important for persons with HIV as they relate to medication adherence. Complex medication regimens and side effects can affect both quality of life and adherence [29–32]. Resistant viral strains

| Table 3: Adjusted health-related quality of life measures, stratified by CD4 count (N = 3772) |
|---------------------------------------------------------------|
| Disability Measure | CD4 <200 (n = 1950) (reference) | CD4 200–499 (n = 812) | CD4 ≥ 500 (n = 259) | CD4 Unknown (n = 751) |
|---------------------|-------------------------------|---------------------|---------------------|---------------------|
| Overall Health      | 45.5 (42.7–48.2)             | 56.8 (53.7–59.9)    | 64.7 (60.3–69.0)    | 49.4 (46.2–52.7)    |
| Pain                | 61.8 (58.6–65.0)             | 67.6 (64.0–71.2)    | 71.6 (66.6–75.6)    | 64.8 (61.0–68.5)    |
| Physical Functioning| 56.6 (53.4–59.7)             | 70.7 (67.2–74.2)    | 78.1 (73.2–83.1)    | 67.0 (63.3–70.7)    |
| Role Functioning    | 41.3 (37.0–45.7)             | 61.9 (57.0–66.7)    | 74.9 (68.0–81.7)    | 58.3 (53.2–63.4)    |
| Social Functioning  | 61.8 (58.7–64.9)             | 75.3 (71.8–78.8)    | 84.3 (79.4–89.1)    | 70.5 (66.9–74.2)    |
| Mental Health       | 57.1 (54.8–59.3)             | 59.1 (56.5–61.6)    | 61.1 (57.5–64.6)    | 58.7 (56.0–61.3)    |
| Energy/Fatigue      | 45.4 (43.0–47.7)             | 53.3 (50.6–55.9)    | 58.8 (55.0–62.5)    | 49.8 (47.0–52.6)    |
| Cognitive Functioning| 71.0 (68.6–73.4)            | 74.2 (71.5–76.9)    | 76.4 (72.7–80.2)    | 78.0 (75.2–80.8)    |

*least-squares means analysis; Tukey-Kramer adjustment for multiple comparisons; significance level P<0.05;  
a significant pairwise difference: CD4 < 200 vs. CD4 200–499;  
b significant pairwise difference: CD4 200–499 vs. CD4 ≥ 500;  
c significant pairwise difference: CD4 < 200 vs. CD4 ≥ 500;  
CL= confidence limit  
factors in model: age, education, sex, race/ethnicity, HIV risk, health insurance status, income time known HIV+, current antiretroviral status, type of recruitment
may emerge when adherence to antiretroviral regimens is suboptimal. After the initial HRQOL module was used, the SHAS questionnaire was modified to include questions on use of past and current medications (including protease inhibitors), duration of current therapies, measures of adherence, and reasons for lack of adherence. These questions should provide valuable new data on the relationship of disease progression, therapy, and HRQOL among participants in the SHAS Project.

Conclusions
The evolution toward treatment of HIV disease as a chronic illness presents additional challenges for patients and clinicians. Measures of health-related quality of life can provide important information to behavioral and clinical studies of antiretroviral treatment, adherence, and viral resistance – factors that ultimately influence HIV-related morbidity and mortality.

Authors' contributions
MLC developed the analysis question, conducted the data analysis, and drafted the manuscript. AKN and AID participated in developing the analysis question, and have contributed to and approved the final manuscript.

References
1. Carpenter CC, Fischl MA and Hamner SM Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel JAMA 1998, 280:78-86
2. Deeks SG, Smith M, Holodniy M and Kahn JO HIV-1 protease inhibitors. A review for clinicians JAMA 1997, 277:145-153
3. Saag MS and Schooley RT Antiretroviral chemotheraphy Current Clinical Topics Infectious Diseases 1998, 18:154-179
4. Centers for Disease Control and Prevention Guidelines for the use of antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV MMWR 2002, 51(RR-7):5-12
5. Centers for Disease Control and Prevention Guidelines for the use of antiretroviral agents among HIV-infected adults and adolescents recommendations of the Panel on Clinical Practices for Treatment of HIV MMWR 2002, 51(RR-7):5-12
6. Lalone L, Clarke AE, Joseph L, Mackenzie T and Grover SA Health-related quality of life with coronary heart disease prevention and treatment J Clinical Epidemiology 2001, 54:1011-1018
7. Janz NK, Janevic MR and Dodge JA Factors influencing quality of life in older women with heart disease Medical Care 2001, 39:588-598
8. Strand V, Tugwell P and Bombardier C Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group Arthritis and Rheumatism 1999, 42:1870-1878
9. Gregg EW, Beckles GL and Williamson DF Diabetes and physical disability among older U.S. adults Diabetes Care 2000, 23:1272-1277
10. Rapp SR, Feldman SR, Exum ML, Fleisher AB Jr and Reboussin DM Psoriasis causes as much disability as other major medical diseases Journal American Academy Dermatology 1999, 41:401-407
11. Arora NK, Gustafson DH and Hawkins RP Impact of surgery on the quality of life of younger women with breast carcinoma: a prospective study Cancer 2001, 92:1288-1298
12. Tsevat J, Sherman SN and McEwhee JA The will to live among HIV-infected patients Annals Internal Medicine 1999, 131:194-198
13. Call SA, Klappro JC and Stewart KE Health-related quality of life and virologic outcomes in an HIV clinic Quality of Life Research 2000, 9:977-985
14. Brechtl JR, Breitbart W, Galletta M, Krivo S and Rosenfeld B The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes Journal Pain & Symptom Management 2001, 21:41-51
15. Wu AW, Rubin HR and Mathews WC Functional status and well-being in a placebo-controlled trial of zidovudine in early symptomatic HIV infection AIDS 1993, 6:452-458
16. Bozette SA, Kanouse DE, Berry S and Duan N Health status and function with zidovudine or zalcitabine as initial therapy for AIDS JAMA 1995, 273:295-301
17. Cohen C, Revicki DA, Nabulsi A, Sarocco PW and Jang P A randomized trial of the effect of ritonavir in maintaining quality of life in advanced HIV disease. Advanced HIV Disease Ritonavir Study Group AIDS 1998, 12:1495-1502
18. Revicki DA, Moyle G and Stellbrink HJ Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter AIDS 1999, 13:851-858
19. Wachtel T, Piette J, Mior V, Stein M, Fleishman J and Carpenter C Quality of life in persons with human immunodeficiency virus infection: measurement validity by the medical outcomes study instrument Annals Internal Medicine 1992, 116:129-137
20. Hays RD, Cunningham WE and Sherbourne CD Health-related quality of life in patients with human immunodeficiency virus infection in the United States: results from the HIV Cost and Services Utilization Study American Journal Medicine 2000, 108:714-722
21. Lubeck DP and Fries JF Health status among persons infected with human immunodeficiency virus. A community-based study Medical Care 1993, 31:269-276
22. Buehler JW, Diaz T and Hersh BS The supplement to HIV/AIDS surveillance project: an approach for monitoring HIV risk behaviors Public Health Rep 1996, 111(Suppl 1):134-137
23. Wu AW, Rubin HR and Mathews WC A health status questionnaire using 30 items from the Medical Outcomes Study. Preliminary validation in persons with early HIV infection Med Care 1991, 29:786-798
24. Stewart AL, Hays RD and Ware JE The MOS short-form general health survey: reliability and validity in a patient population Med Care 1988, 26:724-735
25. Cronbach LJ Coefficient alpha and the internal structure of tests Psychometrika 1951, 16:297-334
26. Weinfert KP, Wilke RJ, Glick HA, Freimuth WW and Schulman KA Relationship between CD4 count, viral burden and quality of life over time in HIV-1-infected patients Med Care 2000, 38:404-410
27. Low-Beer S, Chan K and Wood E Health related quality of life among persons with HIV after the use of protease inhibitors Quality of Life Research 2000, 9:941-949
28. Bing EG, Hays RD and Jacobson JP Health-related quality of life among people with HIV disease: results from the Multicenter AIDS Cohort Study Quality of Life Research 2000, 9:55-63
29. Holzemer WL, Corbett IS and Nokes KM Predictors of self-reported adherence in persons living with HIV disease AIDS Patient Care & STDS 1999, 13:185-197
30. Bucchiardini R, Wu AW and Floridia M Quality of life outcomes of combination zidovudine-didanosine-nevirapine and zidovudine-didanosine for antiretroviral-naive advanced HIV-infected patients AIDS 2000, 14:2567-2574
31. Swindells S, Mohr J and Justis IC Quality of life in patients with human immunodeficiency virus infection: impact of social support, coping style and hopelessness Int J STD AIDS 1999, 10:383-391
32. Catz SL, Kelly JA, Bogart LM, Benosch EG and McAuliffe TL Patterns, correlates, and barriers to medication adherence among persons prescribed new medication for HIV disease Health Psychology 2000, 19:124-133